A combination of Pycnogenol and coenzyme Q10 (CoQ10) appears to improve blood pressure and heart and respiratory rates, according to research published in the journal Panminerva Medica.
A combination of Pycnogenol and coenzyme Q10 (CoQ10) appears to improve blood pressure and heart and respiratory rates, according to research published in the journal Panminerva Medica.
Research on both ingredients continues in the heart health arena, but a relatively new formula containing both ingredients suggests a potential for synergistic benefits.
Researchers at Chieti-Pescara University in Italy recruited 53 patients, 54 to 68 years old, with stable congestive heart failure and mild to moderate hypertension. For 12 weeks, patients were assigned to seven daily capsules of placebo or PycnoQ10, a combination of 15 mg of Pycnogenol and 50 mg of KanekaQ10, marketed by Natural Health Science Inc. (Hoboken, NJ). In addition to study treatments, all patients were on personal heart medications.
Compared to placebo, PycnoQ10 significantly improved heart rate, blood pressure, and respiratory rates.
Blood volume was also increased with PcynoQ10. “As a consequence, the oxygen-rich blood supply to organs improves, and patients become more physically energetic,” said Natural Health Science in a press release on the study.
According to the company, the PycnoQ10 study supports results from previous studies.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.